Johan Jansson

453 total citations
18 papers, 339 citations indexed

About

Johan Jansson is a scholar working on Immunology, Hematology and Molecular Biology. According to data from OpenAlex, Johan Jansson has authored 18 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 10 papers in Hematology and 3 papers in Molecular Biology. Recurrent topics in Johan Jansson's work include Hematopoietic Stem Cell Transplantation (8 papers), T-cell and B-cell Immunology (6 papers) and Immune Cell Function and Interaction (6 papers). Johan Jansson is often cited by papers focused on Hematopoietic Stem Cell Transplantation (8 papers), T-cell and B-cell Immunology (6 papers) and Immune Cell Function and Interaction (6 papers). Johan Jansson collaborates with scholars based in United States, Norway and Japan. Johan Jansson's co-authors include Gaynor A. Smith, Teresia Osborn, Penelope J. Hallett, Ole Isacson, Tristan Lawson, Maria Sundberg, Roger D. Spealman, Helle Bogetofte, Arnar Astradsson and Oliver Cooper and has published in prestigious journals such as Nature Medicine, Blood and The Journal of Immunology.

In The Last Decade

Johan Jansson

14 papers receiving 336 citations

Peers

Johan Jansson
Malcolm Rabie Israel
Martijn Moransard Switzerland
Guillaume Perriard Switzerland
Vanessa Daccach Marques Brazil
Alastair M. Kilpatrick United Kingdom
Sandra Martín-Salamanca Spain
Olivia Domingues Luxembourg
Paul Gontarz United States
Ami V. Patel United States
Kyle Smoot United States
Malcolm Rabie Israel
Johan Jansson
Citations per year, relative to Johan Jansson Johan Jansson (= 1×) peers Malcolm Rabie

Countries citing papers authored by Johan Jansson

Since Specialization
Citations

This map shows the geographic impact of Johan Jansson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Jansson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Jansson more than expected).

Fields of papers citing papers by Johan Jansson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan Jansson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Jansson. The network helps show where Johan Jansson may publish in the future.

Co-authorship network of co-authors of Johan Jansson

This figure shows the co-authorship network connecting the top 25 collaborators of Johan Jansson. A scholar is included among the top collaborators of Johan Jansson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan Jansson. Johan Jansson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Sullivan, Ryan J., Katy K. Tsai, Anna C. Pavlick, et al.. (2025). Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma. Journal of Cancer. 16(13). 3797–3809.
2.
Goto, Tatsunori, Hiroshi Okamura, Takashi Ikeda, et al.. (2025). Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study. International Journal of Hematology. 122(1). 93–105. 1 indexed citations
3.
Chen, Jingjing, Y. Takanami, Johan Jansson, & Guillermo Rossiter. (2024). Practical considerations of promising zone design for interim sample size Re-estimation: An application to GRAPHITE for graft vs host disease. Contemporary Clinical Trials. 148. 107765–107765.
4.
Chen, Yi‐Bin, Mohamad Mohty, Robert Zeiser, et al.. (2024). Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial. Nature Medicine. 30(8). 2277–2287. 20 indexed citations
5.
Chen, Chunlin, et al.. (2024). Population pharmacokinetic modeling of vedolizumab for graft‐versus‐host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant. Pharmacology Research & Perspectives. 12(5). e1257–e1257. 1 indexed citations
6.
Fløisand, Yngvar, Mark A. Schroeder, Patrice Chevallier, et al.. (2021). A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease. Bone Marrow Transplantation. 56(10). 2477–2488. 11 indexed citations
7.
Sandborn, William J., Douglas C. Wolf, Geert D’Haens, et al.. (2020). Sa1880 DOSE ESCALATION OF SUBCUTANEOUS VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: A POST HOC ANALYSIS OF THE VISIBLE TRIAL DATA. Gastroenterology. 158(6). S–463. 1 indexed citations
8.
Sandborn, William J., Silvio Danese, Johan Jansson, et al.. (2020). Sa1879 EFFICACY AND SAFETY OF VEDOLIZUMAB REINITIATION FOLLOWING TREATMENT INTERRUPTION: POST HOC ANALYSIS OF THE VISIBLE TRIAL DATA. Gastroenterology. 158(6). S–462. 1 indexed citations
9.
Sandborn, William J., Douglas C. Wolf, Geert D’Haens, et al.. (2020). P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: A post hoc analysis of the VISIBLE trial data. Journal of Crohn s and Colitis. 14(Supplement_1). S442–S443. 3 indexed citations
10.
Chen, Yi‐Bin, Nirav N. Shah, Anne S. Renteria, et al.. (2019). Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Advances. 3(23). 4136–4146. 30 indexed citations
11.
12.
Smith, Gaynor A., Johan Jansson, Emily M. Rocha, et al.. (2015). Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition. Molecular Neurobiology. 53(8). 5161–5177. 53 indexed citations
13.
Sundberg, Maria, Helle Bogetofte, Tristan Lawson, et al.. (2013). Improved Cell Therapy Protocols for Parkinson's Disease Based on Differentiation Efficiency and Safety of hESC-, hiPSC-, and Non-Human Primate iPSC-Derived Dopaminergic Neurons. Stem Cells. 31(8). 1548–1562. 185 indexed citations
14.
Kuzin, Ihor, et al.. (2012). CD23+CD21highCD1dhigh B Cells in Inflamed Lymph Nodes Are a Locally Differentiated Population with Increased Antigen Capture and Activation Potential. The Journal of Immunology. 188(12). 5944–5953. 18 indexed citations
15.
Jansson, Johan, et al.. (2010). Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects. Leukemia Research. 35(6). 800–807. 6 indexed citations
16.
17.
Jansson, Johan, et al.. (2010). Differential gene expression in acute lymphoblastic leukemia cells surviving allogeneic transplant. Cancer Immunology Immunotherapy. 59(11). 1633–1644. 4 indexed citations
18.
Young, Faith, Andrew Campbell, Johan Jansson, et al.. (2008). High-Risk Acute Lymphoblastic Leukemia Cells with bcr-abl and Ink4a/Arf Mutations Retain Susceptibility to Alloreactive T Cells. Biology of Blood and Marrow Transplantation. 14(6). 622–630. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Malcolm Rabie Breakdown of academic impact, for papers by Martijn Moransard Breakdown of academic impact, for papers by Guillaume Perriard Breakdown of academic impact, for papers by Vanessa Daccach Marques Breakdown of academic impact, for papers by Alastair M. Kilpatrick Breakdown of academic impact, for papers by Sandra Martín-Salamanca Breakdown of academic impact, for papers by Olivia Domingues Breakdown of academic impact, for papers by Paul Gontarz Breakdown of academic impact, for papers by Ami V. Patel Breakdown of academic impact, for papers by Kyle Smoot
Rankless by CCL
2026